Advanced Search

Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 1999 September-October;51(9-10) > Minerva Pediatrica 1999 September-October;51(9-10):309-12



A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532

Frequency: Bi-Monthly

ISSN 0026-4946

Online ISSN 1827-1715


Minerva Pediatrica 1999 September-October;51(9-10):309-12


Cisapride and risk of cardiac complications

Cataldo F.

Cisapride is a prokinetic agent thought to be without severe side effects. Recently, rare cisapride-induced cardiotoxic effects (QT interval prolongation, ventricular arrhythmias) have been reported, raising questions about its safety. Some risk factors have been reported: overdosage of cisapride, association with some drugs inhibiting hepatic metabolism via the cytochrome P450 3A4 enzymatic system (such as azole antifungals, macrolide antibiotics, non sedating antihistamines), other pharmacological agents increasing the parasympathetic tone by raising the effect of cisapride (such as ranitidine and cimetidine), electrolyte abnormalities (such as low serum levels of calcium, potassium and magnesium in the blood), liver dysfunctions, congenital long QT syndrome, and infants born before 36 weeks' gestation, for three months after birth. Physi-cians, prescribing cisapride should pay attention to these risk factors, to avoid the possibility of a rare cardiac adverse effect.

language: Italian


top of page